A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
-
BUSINESS 374 Chugai Employees Apply for Voluntary Redundancy Program
April 28, 2023
-
ACADEMIA More Japan-Specific Data, Stable Supplies of Pfizer’s Stelues Needed amid Syphilis Surge: Specialist
April 27, 2023
-
BUSINESS Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
April 26, 2023
-
BUSINESS Sumitomo Curbs Shipments of Diabetes Hopeful Twymeeg on More-Than-Expected Demands
April 25, 2023
-
REGULATORY Health Ministry Panel OKs Japan’s First Abortion Pill with Official Go-Ahead Set for May
April 24, 2023
-
BUSINESS Drug Makers’ New Grad Hiring in Japan Up 5.8%, Rising for 1st Time since FY2020
April 21, 2023
-
BUSINESS Nippon BI Logs 4% Growth on NHI Price-Based Sales; Jardiance, Ofev as Engines
April 21, 2023
-
ACADEMIA Abortion Pill Is Beneficial as New Option, but Don’t See It as Easy Solution: OB/GYN Association Chair
April 20, 2023
-
REGULATORY Japan to End Priority Review for COVID Drugs and Vaccines after Severity Downgrade: Official
April 20, 2023
-
BUSINESS Ono Aims Higher with Aggressive Open Innovation in Drug Discovery
April 19, 2023
-
BUSINESS Lilly’s Mounjaro Hits Japan Pharmacy Shelves, Mitsubishi as Distributor
April 19, 2023
-
REGULATORY LDP Gathers Steam towards Pharma Policy Proposal Next Month, Sees Honebuto as Make-or-Break Milestone
April 18, 2023
-
REGULATORY Abortion Pill Mefeego’s Japan Panel Review Rescheduled for April 21
April 18, 2023
-
ORGANIZATION Pharma CEOs Call for Japan’s Leadership to Tackle Global Health Issues at G7 Summit
April 17, 2023
-
ORGANIZATION Japan, US, EU Trade Groups Push Price Maintenance during Patent Period: Joint Statement
April 17, 2023
-
BUSINESS AstraZeneca Japan Grows 17% in 2022, Bags 12 Approvals; Up to 7 Filings Eyed for 2023
April 14, 2023
-
BUSINESS Axcelead to Expand Overseas Biz, Shoots for 130 Billion Yen Sales and 5,000-Plus Researchers
April 13, 2023
-
REGULATORY Lawmakers Split 50/50 on Abortion Pill, No Conclusion at LDP Panel
April 13, 2023
-
BUSINESS Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…